Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;44(4):975-982.
doi: 10.1111/dar.14069. Epub 2025 May 9.

Disparities in Opioid Agonist Treatment Accessibility for Priority Populations in New South Wales, Australia

Affiliations

Disparities in Opioid Agonist Treatment Accessibility for Priority Populations in New South Wales, Australia

James H Conigrave et al. Drug Alcohol Rev. 2025 May.

Abstract

Introduction: Opioid agonist treatment (OAT) is effective for managing opioid dependence; however, it can be hard to access in some regions. We investigated OAT access for priority populations living in New South Wales, Australia: Aboriginal and Torres Strait Islander peoples, Culturally and Linguistically Diverse (CALD) peoples, and youth (18-24 years).

Method: Using a linked database, we analysed distances between residential postcodes and OAT dosing points for 29,935 individuals from July 2015 to June 2020. We used multi-level models with random intercepts for clients to assess the relative distance lived from dosing points for members of each priority population.

Results: The median distance to dosing points was 9.80 km. Multi-level regression predicting log-transformed distance (ln) showed, relative to others, Aboriginal and Torres Strait Islander clients lived 89.98% (95% confidence interval [CI] 82.25%, 98.04%) further, and youth lived 15.09% (95% CI 4.70%, 26.52%) further from dosing points. In contrast, CALD individuals lived 35.32% (95% CI 31.88%, 38.58%) closer than others. Multi-level logistic regression showed Aboriginal and Torres Strait Islander clients were 3.39 (95% CI 2.82, 4.07) times more likely to live 50 km or more from their chosen dosing point.

Discussion and conclusion: Aboriginal and Torres Strait Islander Australians and youth have poorer access to OAT dosing points than others in New South Wales. CALD individuals live closer to dosing points, which could suggest better access, or reticence to travel far for care. Targeted interventions are needed to improve OAT accessibility in regional and remote areas.

Keywords: Indigenous peoples; cultural diversity; health services accessibility; opioid substitution treatment; young adult.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Median distances patients live from opioid agonist treatment dosing points by Statistical Area 3 (SA3), by population. (A) shows values for New South Wales, (B) shows values for Greater Sydney. Data based on the New South Wales Controlled Drugs Data Collection dataset. Direct distances measured from centroids of client postcodes to centroids of dosing point postcodes. Black patches indicate an absence of data. That is, fewer than 10 people in those locations accessed New South Wales Controlled Drugs Data Collection dosing points.

References

    1. United Nations Office on Drugs and Crime , World Drug Report 2023 (United Nations, 2023).
    1. J. V. Pergolizzi, Jr. , Raffa R. B., and Rosenblatt M. H., “Opioid Withdrawal Symptoms, a Consequence of Chronic Opioid Use and Opioid Use Disorder: Current Understanding and Approaches to Management,” Journal of Clinical Pharmacy and Therapeutics 45 (2020): 892–903. - PubMed
    1. Gisev N., Bharat C., Larney S., et al., “The Effect of Entry and Retention in Opioid Agonist Treatment on Contact With the Criminal Justice System Among Opioid‐Dependent People: A Retrospective Cohort Study,” Lancet Public Health 2019, no. 4 (2019): e334–e342. - PMC - PubMed
    1. T. Santo, Jr. , Clark B., Hickman M., et al., “Association of Opioid Agonist Treatment With All‐Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta‐Analysis,” JAMA Psychiatry 78 (2021): 979–993. - PMC - PubMed
    1. Degenhardt L., Glantz M., Evans‐Lacko S., et al., “Estimating Treatment Coverage for People With Substance Use Disorders: An Analysis of Data From the World Mental Health Surveys,” World Psychiatry 16 (2017): 299–307. - PMC - PubMed

MeSH terms

Substances

Grants and funding